Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab dose-finding study in pediatric heterozygous familial hypercholesterolemia
2015-003766-85Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia, sponsored by Sanofi. Primary endpoint: Percent change in calculated LDL-C. Started Jun 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on 2015-003766-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003766-85.